CPHI is pharma’s biggest event of the year — an opportunity to uncover innovation at the source, learn about emerging trends, and connect with industry experts.
The event is widely referred to as being at the heart of pharma, and we believe that as an end-to-end, comprehensive CDMO and CRO, Thermo Fisher Scientific is at the heart of CPHI.
Thank you to everyone who visited our booth to explore how we can support your drug research, development, and manufacturing journey as your trusted partner.
If you didn’t get the chance, it’s not too late to connect.
For those who attended our expert-led sessions, we hope the insights shared by our team shed light on your toughest drug development challenges.
If you missed any of our presentations, we’ve got you covered. Below, you’ll find recap blogs of two sessions that sparked some great conversations.
Jennifer Cannon, President of Commercial Operations, shared her thoughts on the power of strategic partnerships to help biotech and pharma companies stay ahead in today’s fast-moving drug development landscape.
Kelly Howard, VP of Commercial Operations for viral vector, mRNA, and cell therapy services, described how flexible financial solutions can help ease the burden of high development costs for advanced therapies.
As always, CPHI Milan 2024 was a fantastic conference, connecting Thermo Fisher Scientific with our industry counterparts in biotechnology and pharmaceutical drug development.
If you didn’t get the chance to visit our booth, it’s not too late to connect. We’d especially love to discuss our AcceleratorTM Drug Development, 360° CDMO and CRO services with you.
As partners, let’s advance your drug research, development, and manufacturing journey.
Whitepaper
Transforming CDMO Partnerships Through Quality
Get an in-depth look into key indicators of CDMO quality, with tools and best practices to drive continuous improvement, strengthen collaboration, and ultimately cultivate trust.
View InfographicBlog
Enter the CRDMO: Reshaping drug development through CRO/CDMO integration
CRDMOs, or integrated contract research, development, and manufacturing organizations, are a trend to watch. Discover five benefits of partnering with one.
Read BlogBlog
The 5 drug development phases
To be deemed a “success,” a new drug must make it through five specific phases: 1) discovery and development, 2) preclinical research, 3) clinical research, 4) FDA review, and 5) safety monitoring.
Read BlogBlog
CDMO 2.0: Three pharma industry trends for 2024 and beyond
Discover three major trends expected in the pharma industry, including turning to flexible manufacturing, embracing digital enablement, and the need for CDMOs deliver transformational value.
Read BlogBlog
The quality lever: Shaping success in CDMO partnerships
Compromising on quality can lead to detrimental impacts on both speed and cost, ultimately affecting the successful development and marketing of new therapies.
Read BlogBlog
Enter the CRDMO: Reshaping drug development through CRO/CDMO integration
CRDMOs, or integrated contract research, development, and manufacturing organizations, are a trend to watch. Discover five benefits of partnering with one.
Read BlogBlog
What is a CDMO? Seven things to look for in a quality CDMO partner
Learn how CDMOs (contract development and manufacturing organizations) work with pharma companies, and the top considerations companies have when choosing a CDMO partner.
Read BlogBlog
CROs vs CMOs, and CDMOs: What’s the difference between the three?
CROs, CMOs, and CDMOs all help biotechnology and pharmaceutical companies with drug development and manufacturing, but what’s the difference between the three?
Read BlogWebinar
Optimizing the cell therapy patient journey through integrated CRO CDMO partnership
Watch this on-demand webinar for insights on how working with a single integrated CRO/CDMO partner can help ease industry challenges and provide an accelerated path from development to manufacturing, as well as the benefits that come from unified teams and infrastructure.
Infographic
CDMO Checklist to Launch Your Molecule Globally
Preparing to take your drug into the global market? You’ll need to make sure your CDMO has what it takes to successfully navigate the global regulatory space with speed, security, and supply safeguards. Use this quick list as a reference when evaluating your options.
View InfographicBlog
Enabling a digital culture through integrated business processes
In contrast to a physical work environment, where stability and experience are key, a digital business environment focuses on innovation and connectivity. Learn more.
Whitepaper
The changing landscape of oncology drug development: Bringing novel lifesaving therapies to patients
Oncology is the fastest-growing, most active sector of drug development. Matching drug products to clinical and commercial needs requires scientific and technological innovation.
View WhitepapereBook
Protecting tomorrow: Supporting sustainability in the pharmaceutical and biotech industries
Learn how Thermo Fisher is meeting its environmental sustainability goals, and how we work in partnership with the pharma and biotech communities on shared environmental sustainability goals.
View eBookInfographic
Preparing biologics for commercialization: Understanding Strategies to Reduce Risk and Optimize Outcomes in Drug Development
Within the drug development process, there are several steps that occur between the laboratory and final manufacture of the drug product. Different players step in during each point, so keeping a program with many moving parts on track requires planning and time-tested execution approaches.
View InfographicWhitepaper
Advancing drug development using in silico modeling
This report provides a framework for that understanding by outlining some of the processes that stand to gain the most from computational modeling and identifying the in silico capabilities that can be used to accelerate and de-risk each phase of development.
Read Whitepaper